Healthcare - Biotechnology - NASDAQ - US
$ 1.1201
-3.44 %
$ 2.29 M
Market Cap
-0.06
P/E
CASH FLOW STATEMENT
-6.41 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
7.61 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Dermata Therapeutics, Inc.
| Net Income | -7.79 M |
| Depreciation & Amortization | 8.04 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 522 K |
| Change in Working Capital | 864 K |
| Others | 494 K |
| Free Cash Flow | -6.41 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (7.8) | (9.6) | (7.9) | (3.2) | (4.7) |
| Depreciation & Amortization | 0 | 0 | 0 | 322 | 1.36 K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 731 |
| Stock Based Compensation | 0.5 | 0.9 | 1.9 | 0 | 731 |
| Other Operating Activities | 0 | 0.9 | 14.1 K | 36.5 K | 0.9 |
| Change in Working Capital | 0.9 | (0.2) | 0.3 | (0.8) | 75 K |
| Cash From Operations | (6.4) | (8.8) | (5.7) | (4.0) | (3.9) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 40 | 0 | (1.0) | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 1.0 | (0.7) | (0.6) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 187 | 287 | (0.4) | 3.2 | 5.4 |
| Cash From Financing Activities | 7.6 | 4.3 | 16.0 | 2.6 | 4.7 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 1.2 | (4.6) | 10.3 | (1.5) | 0.8 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (6.4) | (8.8) | (5.7) | (4.0) | (3.9) |